Christopher D. Roberts has sold BDTX and made no open-market buys since Sep 2020

Christopher D. Roberts, Ph.D., is an individual corporate insider and biotechnology executive who served as Chief Scientific Officer of Black Diamond Therapeutics beginning in September 2019, where he oversaw the company’s research and early development efforts( At Black Diamond, he joined as the company was advancing its precision-oncology platform and lead program, BDTX-189, toward the clinic(

Roberts brings more than two decades of experience in drug discovery and development across oncology and immunology( Before Black Diamond, he was an Entrepreneur in Residence at SR One, GlaxoSmithKline’s corporate venture arm, and previously served as Vice President of Chemistry and Early Development at Syros Pharmaceuticals, where he helped guide oncology assets into clinical development( He later became CEO of Civetta Therapeutics( Roberts earned a B.A. in chemistry from Whitworth University, a Ph.D. in organic chemistry from the University of California, Riverside, and completed a postdoctoral fellowship at the University of Bern in Switzerland(

Written by Perplexity from public sources.